Company intelligence / Profile preview

J INTS BIO

Ownership: Private
Development stage: Phase 1

Overview

J INTS BIO recently presented promising Phase 1/2 clinical results for JIN-A02, showing outstanding therapeutic efficacy in patients with EGFR C797S mutation who developed resistance to existing third-generation EGFR-TKIs. They also presented preclinical results for JIN-001, which demonstrated enhanced tumor suppression when combined with cisplatin against both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells.[2][3]

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

JIN-A02

Beyond the preview

Go deeper on J INTS BIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on J INTS BIO.

Explore the full profile